Abilify. Buy more. Save more.

Deseret News (Salt Lake City) - Drug firms agree to pay $515 million settlement

admin — Tue, 13 Jan 2009 06:16:02 +0000

BOSTON (AP) — Bristol-Myers Squibb Co. and a former subsidiary have agreed to pay more than $515 million to settle federal and state investigations into their drug marketing and pricing practices.
The civil settlement announced Friday resolves a broad array of allegations against Bristol-Myers Squibb, dating from 1994 through 2005.
Among them were a charge that the New York-based pharmaceutical company illegally promoted the sale of Abilify, an anti-psychotic drug, for pediatric use and to treat dementia-related psychoses. Neither use is approved by the U.S. Food and Drug Administration.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

In a statement, Bristol-Myers Squibb said the settlement would not affect the company’s ongoing business with any customers, including the government.
Copyright C 2007 Deseret News Publishing Co.
Provided by ProQuest Information and Learning Company. All rights Reserved.

Caribbean Update - Bristol-Myers Squibb plant to close.(PUERTO RICO)

admin — Mon, 12 Jan 2009 00:31:04 +0000

Bristol-Myers Squibb Co. will close a plant in western Puerto Rico that makes heart disease and diabetes medicine, eliminating 400 jobs, reports AP (Nov. 8, 2007). The closure, due to reduced demand for the medication, will be completed at the end of 2008, said spokeswoman Carmen Velez. The plant, operating for 36 years, produces Pravachol for heart disease and …

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Read the rest of this article with a Free Trial at HighBeam Research.

Chain Drug Review - Abilify gets OK

admin — Wed, 07 Jan 2009 09:01:03 +0000

Abilify has been approved for the treatment of schizophrenia. The new antipsychotic, which is said to offer a combination of proven efficacy and a favorable side-effect profile, is being marketed in a joint arrangement involving Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. Schizophrenia affects more than 2 million Americans.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Where to buy Abilify tablets no rx

admin — Fri, 02 Jan 2009 11:51:03 +0000

Abilify is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Abilify is used for treatment the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adults.Buy cheap Abilify online without prescriptionBefore you take Abilify, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by Abilify.Store Abilify tablets at room temperature away from moisture and heat.Take Abilify exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.Do not take aripiprazole for longer than 6 weeks unless your doctor has told you to. Take each dose with a full glass of water.Abilify can be taken with or without food. Abilify is usually taken once a day. Follow your doctor ’s instructions.Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include drowsiness, vomiting, agitation, aggression, confusion, tremors, fast or slow heart rate, seizure (convulsions), trouble breathing, feeling light-headed, or fainting.

Chain Drug Review - New label

admin — Tue, 30 Dec 2008 18:06:02 +0000

Bristol-Myers Squibb Co. has been given FDA approval of a new label for Sprycel. The new designation recommends a 100-mg starting dose for the product, which treats chronic myeloid leukemia. The company has also announced clearance of Abilify as the first medication for add-on treatment of major depressive disorder.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Drug Cost Management Report - The FDA has approved Abilify™ tablets , a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals - aripiprazole - Product News in Brief

admin — Sun, 28 Dec 2008 22:36:04 +0000

* The FDA has approved Abilify[TM] tablets (aripiprazole), a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals. There is no cure for the devastating brain disorder affecting 2.2 million Americans, but it is treatable, and Abilify has demonstrated a favorable side-effect profile in clinical trials.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation

Psychiatric drugs account for over 12% of PBM spending, higher than any other single therapeutic category, according to AIS’ third quarter 2002 survey of PBMs. Information: www.abilify.com.
COPYRIGHT 2002 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group

Clinical Psychiatry News - Abilify available as oral solution

admin — Tue, 23 Dec 2008 14:56:07 +0000

An oral solution formulation of Abilify (aripiprazole) is now available. Abilify is indicated for the treatment of schizophrenia and for the treatment of acute manic and mixed episodes associated with bipolar disorder. For more information, contact Otsuka America Pharmaceutical Inc., by visiting www.abilify.com, or by calling 800-321-1335.

Related Results

Abilify approvalAbilify approvalNew AbilifyNew ABILIFY formulationAbilify wins clearance

Behavioral Healthcare - New ABILIFY formulation

admin — Sun, 21 Dec 2008 09:16:04 +0000

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., have launched ABILIFY[R] DISCMELT[TM] (aripiprazole) Orally Disintegrating Tablets, an oral form of the antipsychotic medication aripiprazole that disintegrates rapidly in the mouth. The FDA approved ABILIFY DISCMELT on June 7. For full prescribing information, including boxed warning, visit www.abilify.com.

Related Results

Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionAbilify wins clearance

[ILLUSTRATION OMITTED]
COPYRIGHT 2006 Vendome Group LLC
COPYRIGHT 2008 Gale, Cengage Learning

Shared Psychotic Disorder Causes Symptoms Information With Treatment

admin — Thu, 18 Dec 2008 08:16:02 +0000

Shared psychotic disorder has also been referred to by other names such as psychosis of association, contagious insanity, infectious insanity, double insanity, and communicated insanity. This disorder usually occurs only in long-term relationships in which one person is dominant and the other is passive. In most cases, the person in whom the delusions are induced is dependent on or submissive to the person with the psychotic disorder. The people involved often are reclusive or otherwise isolated from society and have close emotional links with each other. The disorder also can occur in groups of individuals who are closely involved with a person who has a psychotic disorder. The disturbance is not better accounted for by another Psychotic Disorder (e.g., Schizophrenia) or a Mood Disorder With Psychotic Features and is not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a general medical condition. The dominating primary case is most commonly represented by persons with schizophrenia, delusions, or mood disorders. In Western countries, both the original delusions in the dominant person and the induced delusions in the submissive person are usually chronic and either persecutory or grandiose in nature. In Japan, acute psychotic reactions have been noted to be delusions of a religious nature.

Causes of Shared Psychotic Disorder

Common Causes and Risk factors of Shared Psychotic Disorder

Social Isolation.

Stress.

Signs and Symptoms of Shared Psychotic Disorder

Sign and Symptoms of Shared Psychotic Disorder

Delusions.

Hallucinations.

Disorganized speech.

Grossly disorganized or catatonic behavior.

Treatment of Shared Psychotic Disorder

Common Treatment of Shared Psychotic Disorder

Atypical newer neuroleptics are the accepted mode of treatment for the spectrum of these disorders.

Newer-generation anticonvulsants are also highly effective for shared psychotic disorder.

Olanzapine/fluoxetine (Symbyax), aripiprazole (Abilify), and quetiapine (Seroquel) are extremely effective in these cases.

Antipsychotic medications also useful for Shared Psychotic Disorder

psychotherapy treating Shared Psychotic Disorder

Family therapy should also be considered to re-establish the nuclear family and to provide social support to modify old family dynamics.

Do not use illegal drugs or drink alcohol, especially when you are taking medicine for this condition.

Antipsychotic Drugs: OK for Dementia Patients?

admin — Sat, 13 Dec 2008 15:11:03 +0000

Oct. 18, 2005 — A new generation of antipsychotic drugs may slightly increase the risk of death when used to treat common behavioral and psychological problems in people with dementia.
The new drugs include Abilify, Zyprexa, Seroquel, and Risperdal.
A new review of clinical trials that treated people with dementia shows 3.5% of those prescribed the drugs died compared with 2.3% of those who took a placebo.
Researchers say most elderly people with dementia develop aggression, delusions, and other psychiatric symptoms; antipsychotic drugs are commonly used to treat those symptoms.
In the last decade a new generation of antipsychotic drugs has largely replaced the older conventional antipsychotics and has become the preferred treatment for behavioral problems associated with dementia. The older generation of drugs was associated with more pronounced side effects.
But researchers say concerns have arisen about possibly increased risk for death, stroke, and quickened mental decline.
Death Risk Tied to Common Dementia Treatment
In the study, which appears in The Journal of the American Medical Association, researchers analyzed information from 15 clinical trials of new antipsychotic drugs in treating people with dementia to see if there was any increased risk of death.
The results showed that death occurred more often among participants who were randomly assigned to receive one of the new antipsychotic drugs than those who received a placebo.
Researchers say most of the studies were 10 to 12 weeks long, and the fact that an increase in the risk of death as well as cerebrovascular events, such as stroke, was found in this short time period is concerning and suggests that these drugs should be used with care.
What to Do
In an editorial that accompanies the study, Peter V. Rabins, MD, MPH, and Constantine G. Lyketsos, MD, MHS, of Johns Hopkins Medical Institutions in Baltimore, say antipsychotic drugs are used to treat the psychological and behavioral symptoms that affect 60% to 90% of people with dementia.
In light of these results, they say other possible causes of behavioral and psychological problems, such as untreated or undertreated medical illnesses, overmedication, and lack of engaging activities, should be considered before treating these symptoms in people with dementia.
In addition, the risks and benefits of treatment with antipsychotic drugs should be weighed for each person. If antipsychotic drugs are prescribed, then careful monitoring is necessary.